Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

摘要: Acute lymphoblastic leukemia (ALL) following solid organ or hematologic malignancy (secondary ALL, s-ALL) is not well characterized. We analyzed the characteristics and outcome of patients with s-ALL compared them those de novo- ALL. Of 448 patients, 24 (5%) had previous neoplasia. Sixteen received cytotoxic therapy (therapy-associated t-ALL), eight (antecedent-malignancy am-ALL). Except for more advanced age in s-ALL, no statistically significant differences were observed WBC count, CNS involvement, immunophenotype cytogenetics between groups, nor complete remission (t-ALL: 94%; am-ALL: 75%; novo-ALL: 85%), 3-year duration (58%; 50%; 72%), overall survival (71%; 38%; 60%) event-free (53%, 53%). Our study did show poor clinical cytogenetic features inferior ALL antecedent neoplastic disease, irrespective type treatment